Основные положения

kpccz

Комплексные проблемы сердечно-сосудистых заболеваний

Complex Issues of Cardiovascular Diseases

2306-12782587-9537

Federal State Budgetary Institution “Research Institute for Complex Issues of Cardiovascular Diseases”

10.17802/2306-1278-2023-12-3-211-219

kpccz-1295

Research Article

ОНЛАЙН. АНАЛИТИЧЕСКИЙ ОБЗОР. Патологическая физиология

СОВРЕМЕННЫЙ ВЗГЛЯД НА РОЛЬ ФАКТОРА РОСТА И ДИФФЕРЕНЦИРОВКИ 15 В ГЕНЕЗЕ, ТЕЧЕНИИ И ИСХОДАХ ПАТОЛОГИИ СЕРДЕЧНО-СОСУДИСТОЙ СИСТЕМЫ

CURRENT VIEWS ON THE ROLE OF GROWTH DIFFERENTIATION FACTOR 15 IN THE GENESIS, COURSE AND OUTCOME OF CARDIOVASCULAR PATHOLOGY

https://orcid.org/0000-0003-0734-9400

Ибрагимова

Регина Энверовна

Ibragimova

Regina E.

ординатор 1 года по специальности «кардиология» федерального государственного бюджетного учреждения «Национальный медицинский исследовательский центр имени В. А. Алмазова» Министерства здравоохранения Российской Федерации, Санкт-Петербург, Российская Федерация

resident of 1st year in the specialty “cardiology”, Federal State Budgetary Institution “Almazov National Medical Research Centre” of the Ministry of Health of the Russian Federation, St. Petersburg, Russian Federation

irregina.2000@mail.ru

https://orcid.org/0000-0002-7384-9705

Захарьян

Елена Аркадьевна

Zakharyan

Elena A.

кандидат медицинских наук доцент кафедры внутренней медицины № 1 института «Медицинская академия имени С.И. Георгиевского» федерального государственного автономного образовательного учреждения высшего образования «Крымский федеральный университет имени В.И. Вернадского», Симферополь, Российская Федерация

PhD, Associate Professor at the Department of Internal Medicine No. 1, Institute “S.I. Georgievsky Medical Academy” of the Federal State Autonomous Educational Institution of Higher Education “Vernadsky Crimean Federal University”, Simferopol, Russian Federation

locren@yandex.ru

Федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр имени В. А. Алмазова» Министерства здравоохранения Российской ФедерацииРоссияFederal State Budgetary Institution “Almazov National Medical Research Centre” of the Ministry of Health of the Russian FederationRussian Federation

Институт «Медицинская академия имени С.И. Георгиевского» федерального государственного автономного образовательного учреждения высшего образования «Крымский федеральный университет имени В.И. Вернадского»РоссияInstitute “S.I. Georgievsky Medical Academy” of the Federal State Autonomous Educational Institution of Higher Education “Vernadsky Crimean Federal University”Russian Federation

2023

25092023

123211219

2023

Ибрагимова Р.Э., Захарьян Е.А.

Ibragimova R.E., Zakharyan E.A.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.nii-kpssz.com/jour/article/view/1295

Основные положения

В статье обобщены данные о влиянии фактора роста и дифференцировки 15 на генез, течение и исходы патологий сердечно-сосудистой системы. Представленный анализ мнений экспертов позволяет приблизиться к ответу на актуальный в научном сообществе вопрос: способствует ли данный фактор прогрессированию сердечно-сосудистых заболеваний или выполняет протекторную функцию.

Аннотация

Фактор роста и дифференцировки 15 (GDF-15) – циркулирующий белок, связанный со множеством патологических процессов, в том числе выступающий маркером раннего развития сердечно-сосудистых заболеваний. Экспрессия GDF-15 в значительной степени индуцируется в кардиомиоцитах после ишемии, реперфузии, перегрузки давлением и механического растяжения, что позволяет использовать его для диагностики субклинического коронарного атеросклероза, артериальной гипертензии и сердечной недостаточности. В данной работе представлен обзор исследований, посвященных определению диагностического спектра данного маркера. Также мы рассмотрели два взгляда на роль GDF-15 в патогенезе сердечно-сосудистой патологии: способствование прогрессированию патологии или выполнение компенсаторной функции. Внедрение высокоспецифичных маркеров, в частности GDF-15, в клиническую практику может способствовать снижению рисков сердечно-сосудистых осложнений, инвалидизации и смертности пациентов.

Highlights

The article summarizes the data on the influence of growth and differentiation factor 15 on the genesis, course and outcomes of cardiovascular system pathologies. The presented analysis of experts' opinions allows to approach the answer to the question, which is topical in the scientific community: whether this factor promotes the progression of cardiovascular diseases or performs a protective function.

Abstract

Growth and differentiation factor 15 (GDF-15) is a circulating protein and is associated with a variety of pathological processes, including being a marker of endothelial dysfunction. GDF-15 expression is upregulated in cardiomyocytes after ischemia, reperfusion, pressure overload and mechanical stretch, allowing it to be used for the diagnosis of subclinical coronary atherosclerosis, arterial hypertension and heart failure. This paper presents a review of studies that have focused on the diagnostic spectrum of this marker. We also considered two perspectives on the role of GDF-15 in the pathogenesis of cardiovascular disease: as a factor contributing to pathology progression or as performing a compensatory function? The introduction of highly specific markers, in particular GDF-15, into clinical practice may help to reduce the risk of cardiovascular complications, disability and mortality.

Фактор роста и дифференцировки 15Эндотелиальная дисфункцияСердечно-сосудистые события

Growth and differentiation factor-15Endothelial dysfunctionCardiovascular events

Исследование выполнено при поддержке гранта Российского научного фонда № 22-25-20053, https://rscf.ru/project/22-25-20053/

References1

Tsai V.W.W., Husaini Y., Sainsbury A., Brown D.A., Breit S.N. The MIC-1/GDF15- GFRAL pathway in energy homeostasis: implications for obesity, cachexia, and other associated diseases. Cell Metabolism. 2018;28(3):353–368. doi:10.1016/j.cmet.2018.07.018.

Tsai V.W.W., Husaini Y., Sainsbury A. et al. The MIC-1/GDF15- GFRAL pathway in energy homeostasis: implications for obesity, cachexia, and other associated diseases. Cell Metabolism. 2018;28(3):353–368. doi:10.1016/j.cmet.2018.07.018.

Wollert K.C., Kempf T., Wallentin L. Growth differentiation factor 15 as a biomarker in cardiovascular disease. Clinical Chemistry. 2017;63(1):140–151. doi:10.1373/clinchem.2016.255174.

Wollert K.C., Kempf T., Wallentin L.Growth differentiation factor 15 as a biomarker in cardiovascular disease. Clinical Chemistry. 2017;63(1):140–151. doi:10.1373/clinchem.2016.255174.

Lawton L.N., Bonaldo M.F., Jelenc P.C., Qiu L., Baumes S.A., Marcelino R.A., de Jesus G.M., Wellington S., Knowles J.A., Warburton D., Brown S., Soares M.B. Identification of a novel member of the TGF-beta superfamily highly expressed in human placenta. Gene. 1997;203 (1):17–26. doi:10.1016/s0378-1119(97)00485-x.

Lawton L.N., Bonaldo M.F., Jelenc P.C. et al. Identification of a novel member of the TGF-beta superfamily highly expressed in human placenta. Gene. 1997;203 (1):17–26. doi:10.1016/s0378-1119(97)00485-x.

Fairlie W.D., Moore A.G., Bauskin A.R., Russell P.K., Zhang H.P., Breit S.N. MIC-1 is a novel TGF-β superfamily cytokine associated with macrophage activation. Journal of Leukocyte Biology.1999;65(1):2–5. doi:10.1002/jlb.65.1.2.

Fairlie W.D., Moore A.G., Bauskin A.R. et al. MIC-1 is a novel TGF-β superfamily cytokine associated with macrophage activation. Journal of Leukocyte Biology.1999;65(1):2–5. doi:10.1002/jlb.65.1.2.

Coll A.P., Chen M., Taskar P., Rimmington D., Patel S., Tadross J.A., Cimino I., Yang M., Welsh P., Virtue S., et al. GDF15 Mediates the Effects of Metformin on Body Weight and Energy Balance. Nature. 2020;578(7795):444–8. doi: 10.1038/s41586-019-1911-y

Coll A.P., Chen M., Taskar P. et al. GDF15 Mediates the Effects of Metformin on Body Weight and Energy Balance. Nature. 2020;578(7795):444–8. doi: 10.1038/s41586-019-1911-y

Du W., Piek A., Schouten E.M., van de Kolk C.W.A., Mueller C., Mebazaa A., Voors A.A., de Boer R.A., Silljé H.H.W. Plasma levels of heart failure biomarkers are primarily a reflection of extracardiac production. Theranostics. 2018;8(15):4155–4169. doi:10.7150/thno.26055.

Du W., Piek A., Schouten E.M. et al. Plasma levels of heart failure biomarkers are primarily a reflection of extracardiac production. Theranostics. 2018;8(15):4155–4169. doi:10.7150/thno.26055.

Wang J., Tan G.J., Han L.N., Bai Y.Y., He M., Liu H.B. Novel biomarkers for cardiovascular risk prediction. J Geriatr Cardiol. 2017;14 (2):135–150. doi: 10.11909/j.issn.1671-5411.2017.02.008.

Wang J., Tan G.J., Han L.N. et al. Novel biomarkers for cardiovascular risk prediction. Journal of Geriatric Cardiology. 2017;14 (2):135–150. doi: 10.11909/j.issn.1671-5411.2017.02.008.

Tuegel C., Katz R., Alam M., Bhat Z., Bellovich K., de Boer I., Brosius F., Gadegbeku C., Gipson D., Hawkins J., Himmelfarb J., Ju W., Kestenbaum B., Kretzler M., Robinson-Cohen C., Steigerwalt S., Bansal N. GDF-15, galectin 3, soluble ST2, and risk of mortality and cardiovascular events in CKD. Am J Kidney Dis.2018;72(4):519–528. doi:10.1053/j.ajkd.2018.03.025.

Tuegel C., Katz R., Alam M. et al. GDF-15, galectin 3, soluble ST2, and risk of mortality and cardiovascular events in CKD. American Journal of Kidney Diseases. 2018;72(4):519–528. doi:10.1053/j.ajkd.2018.03.025.

Adela R., Banerjee S.K. GDF-15 as a target and biomarker for diabetes and cardiovascular diseases: a translational prospective. J Diabetes Res. 2015;2015:490842. doi: 10.1155/2015/490842.

Adela R., Banerjee S.K. GDF-15 as a target and biomarker for diabetes and cardiovascular diseases: a translational prospective. Journal of Diabetes Research. 2015;2015:490842. doi: 10.1155/2015/490842.

Wallentin L., Hijazi Z., Andersson U., Alexander J.H., De Caterina R., Hanna M., Horowitz J.D., Hylek E.M., Lopes R.D., Asberg S., Granger C.B., Siegbahn A.; ARISTOTLE Investigators.. Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial. Circulation. 2014;130(21):1847–1858. doi:10.1161/CIRCULATIONAHA.114.011204.

Wallentin L., Hijazi Z., Andersson U. et al. Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial. Circulation. 2014;130(21):1847–1858. doi:10.1161/CIRCULATIONAHA.114.011204.

Luan H.H., Wang A., Hilliard B.K., Carvalho F., Rosen C.E., Ahasic A.M., Herzog E.L., Kang I., Pisani M.A., Yu S., Zhang C., Ring A.M., Young L.H., Medzhitov R. GDF15 is an inflammation-induced central mediator of tissue tolerance. Cell. 2019;178(5):1231-1244. doi:10.1016/j.cell.2019.07.033.

Luan H.H., Wang A., Hilliard B.K. et al. GDF15 is an inflammation-induced central mediator of tissue tolerance. Cell. 2019;178(5):1231-1244. doi:10.1016/j.cell.2019.07.033.

Тишкова О.Г., Дикарева Л.В., Шварев Е.Г., Уханова Ю.Ю. Роль фактора дифференцировки роста-15 (GDF-15) в регуляции и развитии осложнений беременности. Астраханский медицинский журнал. 2022;17(1):14-22. doi:10.48612/agmu/2022.17.1.14.22.

Chow S.L., Maisel A.S., Anand I. et al. Role of biomarkers for the prevention, assessment, and management of heart failure: A scientific statement from the American Heart Association. Circulation. 2017;135(22):e1054-e1091. doi: 10.1161/CIR.0000000000000490.

Chow S.L., Maisel A.S., Anand I., Bozkurt B., de Boer R.A., Felker G.M., Fonarow G.C., Greenberg B., Januzzi J.L. Jr, Kiernan M.S., Liu P.P., Wang T.J., et al. Role of biomarkers for the prevention, assessment, and management of heart failure: A scientific statement from the American Heart Association. Circulation. 2017;135(22):e1054-e1091. doi: 10.1161/CIR.0000000000000490.

Unsicker K., Spittau B., Krieglstein K. The multiple facets of the TGF-beta family cytokine growth/differentiation factor-15/macrophage inhibitory cytokine-1. Cytokine & Growth Factor Reviews. 2013;24 (4):373–384. doi:10.1016/j. cytogfr.2013.05.003.

Unsicker K., Spittau B., Krieglstein K. The multiple facets of the TGF-beta family cytokine growth/differentiation factor-15/macrophage inhibitory cytokine-1. Cytokine Growth Factor Rev.2013;24 (4):373–384. doi:10.1016/j. cytogfr.2013.05.003.

Derynck R., Zhang Y.E. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature. 2003;425(6958):577–584. doi:10.1038/nature02006.

Kempf T., Eden M., Strelau J. et al. The transforming growth factor-β superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. Circulation Research. 2006;98(3):351–360. doi: 10.1161/01.RES.0000202805.73038.48.

Kempf T., Eden M., Strelau J., Naguib M., Willenbockel C., Tongers J., Heineke J., Kotlarz D., Xu J., Molkentin J.D., Niessen H.W., Drexler H., Wollert K.C. The transforming growth factor-β superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. Circ Res.2006;98(3):351–360. doi: 10.1161/01.RES.0000202805.73038.48.

Bauskin A. R., Brown D. A., Junankar S. et al. The propeptide mediates formation of stromal stores of PROMIC-1: role in determining prostate cancer outcome. Cancer Research. 2005;65(6):2330–2336. doi: 10.1158/0008-5472.can-04-3827.

Bauskin A. R., Brown D. A., Junankar S., Rasiah K.K., Eggleton S., Hunter M., Liu T., Smith D., Kuffner T., Pankhurst G.J., Johnen H., Russell P.J., Barret W., Stricker P.D., Grygiel J.J., Kench J.G., Henshall S.M., Sutherland R.L., Breit S.N. The propeptide mediates formation of stromal stores of PROMIC-1: role in determining prostate cancer outcome. Cancer Res. 2005;65(6):2330–2336. doi: 10.1158/0008-5472.can-04-3827.

Lok S. I., Winkens B., Goldschmeding R. et al. Circulating growth differentiation factor-15 correlates with myocardial fibrosis in patients with non-ischaemic dilated cardiomyopathy decreases rapidly after left ventricular assist device support. European Journal of Heart Failure. 2012;14(11):1249–1256. doi: 10.1093/eurjhf/hfs120.

Ho F.M., Lin W.W., Chen B.C., Chao C.M., Yang C.R., Lin L.Y., Lai C.C., Liu S.H., Liau C.S. High glucose-induced apoptosis in human vascular endothelial cells is mediated through NF-kappaB and c-Jun NH2-terminal kinase pathway and prevented by PI3K/Akt/eNOS pathway. Cell Signal. 2006;18(3):391–399. doi: 10.1016/j.cellsig.2005.05.009.

Wang, L. Wei, X. Yang, Zhong J.. Roles of growth differentiation factor 15 in atherosclerosis and coronary artery disease. Journal of the American Heart Association. 2019;8(17):e012826. doi:10.1161/JAHA.119.012826.

Li J., Yang L., Qin W., Zhang G., Yuan J., Wang F. Adaptive induction of growth differentiation factor 15 attenuates endothelial cell apoptosis in response to high glucose stimulus. PLoS ONE. 2013;8(6). doi: 10.1371/journal.pone.0065549.e65549

Rohatgi A., Patel P., Das S.R. et al. Association of growth differentiation factor-15 with coronary atherosclerosis and mortality in a young, multiethnic population: observations from the Dallas heart study. Clinical Chemistry. 2012;58(1):172–182. doi:0.1373clinchem.2011.171926.

Lok S. I., Winkens B., Goldschmeding R., van Geffen A.J., Nous F.M., van Kuik J., van der Weide P., Klöpping C., Kirkels J.H., Lahpor J.R., Doevendans P.A., de Jonge N., de Weger R.A. Circulating growth differentiation factor-15 correlates with myocardial fibrosis in patients with non-ischaemic dilated cardiomyopathy decreases rapidly after left ventricular assist device support. Eur J Heart Fail. 2012;14(11):1249–1256. doi: 10.1093/eurjhf/hfs120.

Brown D.A., Breit S.N., Buring J. et al. Concentration in plasma of macrophage inhibitory cytokine-1 and risk of cardiovascular events in women: a nested case-control study. Lancet. 2002;359(9324):2159–2163. doi:10.1016/s0140-6736(02)09093-1.

Wang L., Wei X. Yang Zhong J. Roles of growth differentiation factor 15 in atherosclerosis and coronary artery disease. J Am Heart Assoc. 2019;8(17):e012826. doi:10.1161/JAHA.119.012826.

Daniels L.B., Clopton P., Laughlin G.A. et al. Growth- differentiation factor-15 is a robust, independent predictor of 11-year mortality risk in community-dwelling older adults: the Rancho Bernardo Study. Circulation. 2011;123(19):2101–2110. doi:10.1161/CIRCULATIONAHA.110.979740.

Rohatgi A., Patel P., Das S.R., Ayers C.R., Khera A., Martinez-Rumayor A., Berry J.D., McGuire D.K., de Lemos J.A. Association of growth differentiation factor-15 with coronary atherosclerosis and mortality in a young, multiethnic population: observations from the Dallas heart study. Clinical Chemistry. 2012;58(1):172–182. doi:0.1373clinchem.2011.171926.

Lind L., Wallentin L., Kempf T. et al. Growth-differentiation factor-15 is an independent marker of cardiovascular dysfunction and disease in the elderly: results from the prospective investigation of the vasculature in uppsala seniors (PIVUS) study. European Heart Journal. 2009;30 (19):2346–2353. doi:10.1093/eurheartj/ehp261.

Brown D.A., Breit S.N., Buring J., Fairlie W.D., Bauskin A.R., Liu T., Ridker P.M. Concentration in plasma of macrophage inhibitory cytokine-1 and risk of cardiovascular events in women: a nested case-control study. Lancet. 2002;359(9324):2159–2163. doi:10.1016/s0140-6736(02)09093-1.

Dominguez-Rodriguez A., Abreu-Gonzalez P., Avanzas P., Consuegra-Sanchez L.. Effect of serum growth differentiation factor-15 and the syntax score on 2-year outcomes in patients with acute coronary syndrome. American Journal of Cardiology. 2016;117(10):1569–1574. doi:10.1016/j.amjcard.2016.02.031.

Daniels L.B., Clopton P., Laughlin G.A., Maisel A.S., Barrett-Connor E. Growth- differentiation factor-15 is a robust, independent predictor of 11-year mortality risk in community-dwelling older adults: the Rancho Bernardo Study. Circulation. 2011;123(19):2101–2110. doi:10.1161/CIRCULATIONAHA.110.979740.

Wallentin L., Lindholm D., Siegbahn A. et al. Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST- elevation acute coronary syndrome patients managed with or without in-hospitalrevascularization: a substudy from the prospective randomized platelet inhibition and patient outcomes (PLATO) trial. Circulation. 2014;129 (3):293–303. doi:10.1161/CIRCULATIONAHA.113.004420.

Lind L., Wallentin L., Kempf T., Tapken H., Quint A., Lindahl B., Olofsson S., Venge P., Larsson A., Hulthe J., Elmgren A., Wollert K.C. Growth-differentiation factor-15 is an independent marker of cardiovascular dysfunction and disease in the elderly: results from the prospective investigation of the vasculature in uppsala seniors (PIVUS) study. Eur Heart J.2009;30 (19):2346–2353. doi:10.1093/eurheartj/ehp261.

Kempf T., Zarbock A., Widera C. et al. GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice. Nature Medicine. 2011;17 (5):581–588. doi:10.1038/nm.2354.

Bonaterra G.A., Struck N., Zuegel S., Schwarz A., Mey L., Schwarzbach H., Strelau J., Kinscherf R. Characterization of atherosclerotic plaques in blood vessels with low oxygenated blood and blood pressure (Pulmonary trunk): role of growth differentiation factor-15 (GDF-15). BMC Cardiovasc Disord. 2021;21(1):601. doi: 10.1186/s12872-021-02420-9.

Jeremias I., Kupatt C., Martin-Villalba A. et al. Involvement of CD95/Apo1/Fas in cell death after myocardial ischemia. Circulation. 2000;102:915–920. doi: 10.1161/01.cir.102.8.915.

Kurrelmeyer K.M., Michael L.H., Baumgarten G. et al. Endogenous tumor necrosis factor protects the adult cardiac myocyte against ischemic-induced apoptosis in a murine model of acute myocardial infarction. Proceedings of the National Academy of Sciences. 2000;97:5456 –5461. doi: 10.1073/pnas.070036297.

Kempf T., Zarbock A., Widera C., Butz S., Stadtmann A., Rossaint J., Bolomini-Vittori M., Korf-Klingebiel M., Napp L.C., Hansen B., Kanwischer A., Bavendiek U., Beutel G., Hapke M., Sauer M.G., Laudanna C., Hogg N., Vestweber D., Wollert K.C. GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice. Nature Medicine. 2011;17 (5):581–588. doi:10.1038/nm.2354.

Сабирзянова А.А., Галявич А.С., Балеева Л.В., Галеева З.М. Фактор дифференцировки роста-15 у пациентов в острой стадии инфаркта миокарда. Кардиология. 2020;60(11):42-48. [Sabirzyanova A.A., Galyavich A.S., Baleeva L.V., Galeeva Z.M. Level of the growth differentiation factor-15 in patients with acute myocardial infarction. Kardiologiia. 2020;60(11):42–48. (In Russ)]

2021 Рекомендации ESC по профилактике сердечно-сосудистых заболеваний в клинической практике. Российский кардиологический журнал. 2022;27(7):5155. doi:10.15829/1560-4071-2022-5155

S ̈okmen E., Uçar C., Sivri S. et al. Association between growth differentiation factor 15 and non-dipping circadian pattern in patients with newly diagnosed essential hypertension. Medical Principles and Practice. 2019;28 (6):566–572. doi:10.1159/000501096.

S ̈okmen E., Uçar C., Sivri S., Çelik M., Boduroğlu Y., Erer M., Yıldırım A., İlanbey B. Association between growth differentiation factor 15 and non-dipping circadian pattern in patients with newly diagnosed essential hypertension. Med Princ Pract.2019;28 (6):566–572. doi:10.1159/000501096.

Сиволап В.Д., Земляний Я.В. Порівняльна оцінка впливу кандесартану та раміприлу на рівні GDF 15 і NTproBNP, структурно-функціональні показники серця у хворих на ішемічну хворобу серця з безсимптомною діастолічною дисфункцією, які перенесли інфаркт міокарда на тлі артеріальної гіпертензії. 2014;1:36-40. [Sivolap V.D, Zemlianoy Y.V. Comparative assessment of the effect of candesartan and ramipril on the levels of GDF 15 and NTproBNP, structural and functional parameters of the heart in patients with coronary heart disease with asymptomatic diastolic dysfunction who have had myocardial infarction against the background of arterial hypertension. 2014;1:36-40. (In Ukr)]

Lewis G. A., Rosala-Hallas A., Dodd S. Characteristics Associated With Growth Differentiation Factor 15 in Heart Failure With Preserved Ejection Fraction and the Impact of Pirfenidone. J Am Heart Assoc.2022;11(14):e024668. doi:10.1161/JAHA.121.024668

Гуревич М. А. Артериальная гипертония и хроническая сердечная недостаточность-единство патогенеза и принципов лечения. Российский кардиологический журнал. 2005;6:91-95. [Gurevich M.A. Arterial hypertension and chronic heart failure - common pathogenesis and treatment principles. Russian Journal of Cardiology. 2005;(6):91-95. (In Russ)]

Hillege H.L., Nitsch D., Pfeffer M.A., Swedberg K., McMurray J.J., Yusuf S., Granger C.B., Michelson E.L., Ostergren J., Cornel J.H., de Zeeuw D., Pocock S., van Veldhuisen D.J.; Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Investigators. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation. 2006;113 (5):671–678. doi:10.1161/CIRCULATIONAHA.105.580506

Zhu L., Li C., Liu Q. et al. Molecular biomarkers in cardiac hypertrophy. Journal of Cellular and Molecular Medicine. 2019;23(3):1671-1677. doi:10.1111/jcmm.14129.

Драпкина О. М., Палаткина Л. О. Маркеры цитокиновой активации и оксидативного стресса у больных хронической сердечной недостаточностью. Журнал сердечная недостаточность. 2013;14(6):341-346. doi:10.1007/s00392-021-01944-6.

Lewis G. A., Rosala-Hallas A., Dodd S. Characteristics Associated With Growth Differentiation Factor 15 in Heart Failure With Preserved Ejection Fraction and the Impact of Pirfenidone. Journal of the American Heart Association. 2022;11(14):e024668. doi:10.1161/JAHA.121.024668

Кривошеева Е.Н., Кропачева Е.С., Добровольский А.Б., Титаева Е.В., Панченко Е.П.Ростовой фактор дифференцировки-15 и риск сердечно-сосудистых осложнений у пациентов с фибрилляцией предсердий после планового чрескожного коронарного вмешательства. Российский кардиологический журнал. 2021;26(7):24-30. doi:10.15829/1560-4071-2021-4457

Hillege H.L., Nitsch D., Pfeffer M.A. et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation. 2006;113 (5):671–678. doi:10.1161/CIRCULATIONAHA.105.580506

Hijazi Z., Oldgren J., Lindbäck J., Alexander J.H., Connolly S.J., Eikelboom J.W., Ezekowitz M.D., Held C., Hylek E.M., Lopes R.D., Siegbahn A., Yusuf S., Granger C.B., Wallentin L.; ARISTOTLE and RE-LY Investigators. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. The Lancet. 2016;387(10035):2302-11. doi:10.1016/s0140- 6736(16)00741-8.

Berg D., Ruff C., Jarolim P., Giugliano R.P., Nordio F., Lanz H.J., Mercuri M.F., Antman E.M., Braunwald E., Morrow D..A. Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI Circulation. 2019;139(6):760-71. doi:10.1161/circulationaha.118.038312.

Ueland T., Gullestad L., Kou L. et al. Growth differentiation factor 15 predicts poor prognosis in patients with heart failure and reduced ejection fraction and anemia: results from RED-HF. Clinical Research in Cardiology. 2022;111(4):440-450. doi:10.1007/s00392-021-01944-6.

Carstensen M., Herder C., Brunner E.J.S., Strassburger K., Tabak A.G., Roden M., Witte D.R. Macrophage inhibitory cytokine-1 is increased in individuals before type 2 diabetes diagnosis but is not an independent predictor of type 2 diabetes: the Whitehall II study. Eur J Endocrinol.2010;162(5):913–917. doi:10.1530/EJE-09-1066.

Кривошеева Е.Н., Кропачева Е.С., Добровольский А.Б. и др. Ростовой фактор дифференцировки-15 и риск сердечно-сосудистых осложнений у пациентов с фибрилляцией предсердий после планового чрескожного коронарного вмешательства. Российский кардиологический журнал. 2021;26(7):4457. [Krivosheeva E.N., Kropacheva E.S., Dobrovolsky A.B. et al. Growth differentiation factor 15 and the risk of cardiovascular events in patients with atrial fibrillation after elective percutaneous coronary intervention. Russian Journal of Cardiology. 2021;26(7):4457.(In Russ)] doi:10.15829/1560-4071-2021-4457

Dostalova I., Roubicek T., Bartlova M., Mráz M,, Lacinová Z,, Haluzíková D,, Kaválková P,, Matoulek M,, Kasalicky M,, Haluzík M. Increased serum concentrations of macrophage inhibitory cytokine-1 in patients with obesity and type 2 diabetes mellitus: the influence of very low calorie diet. Eur J Endocrinol.2009;161(3):397–404. doi:10.1530/EJE-09-0417.

Carstensen M., Herder C., Brunner E.J., S et al. Macrophage inhibitory cytokine-1 is increased in individuals before type 2 diabetes diagnosis but is not an independent predictor of type 2 diabetes: the Whitehall II study, Eur. J. Endocrinol. 2010;162(5):913–917. doi:10.1530/EJE-09-1066.

Carlsson A.C., Nowak C., Lind L., Östgren C.J., Nyström F.H., Sundström J., Carrero J.J., Riserus U., Ingelsson E., Fall T., Ärnlöv J. Growth differentiation factor 15 (GDF-15) is a potential biomarker of both diabetic kidney disease and future cardiovascular events in cohorts of individuals with type 2 diabetes: a proteomics approach. Ups J Med Sci.. 2020;125 (1):37–43. doi:10.1080/03009734.2019.1696430.

Dostalova I., Roubicek T., Bartlova M. et al. Increased serum concentrations of macrophage inhibitory cytokine-1 in patients with obesity and type 2 diabetes mellitus: the influence of very low calorie diet. European Journal of Endocrinology. 2009;161(3):397–404. doi:10.1530/EJE-09-0417.

Viola J., Soehnlein O. Atherosclerosis–a matter of unresolved inflammation. Seminars in immunology. Academic Press. 2015; 27(3):184-193.

Carlsson A.C., Nowak C., Lind L. et al. Growth differentiation factor 15 (GDF-15) is a potential biomarker of both diabetic kidney disease and future cardiovascular events in cohorts of individuals with type 2 diabetes: a proteomics approach. Upsala Journal of Medical Sciences. 2020;125 (1):37–43. doi:10.1080/03009734.2019.1696430.

Jeremias I., Kupatt C., Martin-Villalba A., Habazettl H., Schenkel J., Boekstegers P., Debatin K.M. Involvement of CD95/Apo1/Fas in cell death after myocardial ischemia. Circulation. 2000;102:915–920. doi: 10.1161/01.cir.102.8.915.

Shimano M., Ouchi N., Walsh K. Cardiokines: recent progress in elucidating the cardiac secretome.Circulation. 2012;126(21): e327-e332. doi:10.1161/CIRCULATIONAHA.112.150656

Kurrelmeyer K.M., Michael L.H., Baumgarten G., Taffet G.E., Peschon J.J., Sivasubramanian N., Entman M.L., Mann D.L. Endogenous tumor necrosis factor protects the adult cardiac myocyte against ischemic-induced apoptosis in a murine model of acute myocardial infarction. Proc Natl Acad Sci U S A. 2000;97:5456 –5461. doi:10.1073/pnas.070036297.

Babalghith A.O., Al-kuraishy H.M., Al-Gareeb A.I. et al. The potential role of growth differentiation factor 15 in COVID-19: a corollary subjective effect or not? Diagnostics. 2022;12(9):2051. doi:10.3390/diagnostics12092051

Al-Kuraishy H.M., Al-Gareeb A.I., Alblihed M. et al. COVID-19 and risk of acute ischemic stroke and acute lung injury in patients with type ii diabetes mellitus: the anti-inflammatory role of metformin. Frontiers in Medicine. 2021;8:644295. doi:10.3389/fmed.2021.644295.

Wischhusen J., Melero I., Fridman W.H. Growth/Differentiation Factor-15 (GDF-15): From Biomarker to Novel Targetable Immune Checkpoint. Front Immunol. 2020 May 19;11:951. doi: 10.3389/fimmu.2020.00951

Shimano M., Ouchi N., Walsh K. Cardiokines: recent progress in elucidating the cardiac secretome.Circulation. 2012;126(21): e327-e332. doi:10.1161/CIRCULATIONAHA.112.150656

Babalghith A.O., Al-kuraishy H.M., Al-Gareeb A.I., De Waard M., Sabatier J.M., Saad H.M., Batiha G.E. The potential role of growth differentiation factor 15 in COVID-19: a corollary subjective effect or not? Diagnostics. 2022;12(9):2051. doi:10.3390/diagnostics12092051

Iglesias P., Silvestre R.A., Díez J.J. Growth differentiation factor 15 (GDF-15) in endocrinology. Endocrine. 2023; 81:419–431. doi.: 10.1007/s12020-023-03377-9

Al-Kuraishy H.M., Al-Gareeb A.I., Alblihed M., Cruz-Martins N., Batiha G.E. COVID-19 and risk of acute ischemic stroke and acute lung injury in patients with type ii diabetes mellitus: the anti-inflammatory role of metformin. Front Med (Lausanne). 2021;8:110. doi:10.3389/fmed.2021.644295.

The authors declare that there are no conflicts of interest present.